Rheumatoid factor, not antibodies against citrullinated proteins, is associated with baseline disease activity in rheumatoid arthritis clinical trials

Rheumatoid Factor as a Potentiator of Anti-Citrullinated Protein Antibody-Mediated Inflammation in Rheumatoid Arthritis

(2014) Jeremy Sokolove et al.   Arthritis & Rheumatology

Characterization of proposed human B-1 cells reveals pre-plasmablast phenotype

(2013) K. Covens et al.   BLOOD

B-cell targeted therapeutics in clinical development

(2013) Stephan Blüml et al.   ARTHRITIS RESEARCH & THERAPY

Serological changes in the course of traditional and biological disease modifying therapy of rheumatoid arthritis

(2012) Christoph Böhler et al.   ANNALS OF THE RHEUMATIC DISEASES

Rheumatoid factor determines structural progression of rheumatoid arthritis dependent and independent of disease activity

(2012) Daniel Aletaha et al.   ANNALS OF THE RHEUMATIC DISEASES

B-1 B Cell Development in the Fetus and Adult

(2012) Encarnacion Montecino-Rodriguez et al.   IMMUNITY

Induction of osteoclastogenesis and bone loss by human autoantibodies against citrullinated vimentin

(2012) Ulrike Harre et al.   JOURNAL OF CLINICAL INVESTIGATION

Inflammatory bone loss: pathogenesis and therapeutic intervention

(2012) Kurt Redlich et al.   NATURE REVIEWS DRUG DISCOVERY

Should rheumatoid factor in rheumatoid arthritis be sent to Davy Jones’s Locker?

(2012) E Besada et al.   SCANDINAVIAN JOURNAL OF RHEUMATOLOGY

Human B1 cells in umbilical cord and adult peripheral blood express the novel phenotype CD20+CD27+CD43+CD70−

(2011) Daniel O. Griffin et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Combining anti-cyclic citrullinated peptide with the American College of Rheumatology 1987 criteria failed to improve early rheumatoid arthritis diagnosis in the community-based very early arthritis cohort

(2011) X. Le Loet et al.   RHEUMATOLOGY

2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative

(2010) D. Aletaha et al.   ANNALS OF THE RHEUMATIC DISEASES

Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial

(2010) P. P. Tak et al.   ANNALS OF THE RHEUMATIC DISEASES

The likelihood of persistent arthritis increases with the level of anti-citrullinated peptide antibody and immunoglobulin M rheumatoid factor: a longitudinal study of 376 patients with very early undifferentiated arthritis

(2010) Maria D Mjaavatten et al.   ARTHRITIS RESEARCH & THERAPY

Golimumab, a human anti-tumor necrosis factor α monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: Twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis

(2009) Paul Emery et al.   ARTHRITIS AND RHEUMATISM

Autoantibodies and the Risk of Cardiovascular Events

(2009) K. P. LIANG et al.   JOURNAL OF RHEUMATOLOGY

Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor α inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial

(2009) Josef S Smolen et al.   LANCET

B-cell-directed therapies for autoimmune disease

(2009) Thomas Dörner et al.   Nature Reviews Rheumatology

Different properties of ACPA and IgM-RF derived from a large dataset: further evidence of two distinct autoantibody systems

(2009) Jennie Ursum et al.   ARTHRITIS RESEARCH & THERAPY

Golimumab, a human antibody to tumour necrosis factor   given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study

(2008) E C Keystone et al.   ANNALS OF THE RHEUMATIC DISEASES

Inverse Association Between Obesity and Antinuclear Antibodies in Women

(2008) ALMEIDA GONZÁLEZ et al.   JOURNAL OF RHEUMATOLOGY